Compare FORTY & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORTY | NVCR |
|---|---|---|
| Founded | 1985 | 2000 |
| Country | Israel | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 1998 | 2015 |
| Metric | FORTY | NVCR |
|---|---|---|
| Price | $114.00 | $16.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.08 |
| AVG Volume (30 Days) | 403.0 | ★ 934.5K |
| Earning Date | 05-21-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | N/A | $7.72 |
| Revenue Next Year | N/A | $6.74 |
| P/E Ratio | $36.65 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $102.01 | $9.82 |
| 52 Week High | $190.56 | $21.45 |
| Indicator | FORTY | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 47.09 | 47.26 |
| Support Level | $109.49 | $16.33 |
| Resistance Level | $119.68 | $18.43 |
| Average True Range (ATR) | 1.46 | 0.67 |
| MACD | 0.54 | -0.02 |
| Stochastic Oscillator | 37.86 | 45.84 |
Formula Systems (1985) Ltd is an information technology company that is principally engaged through its directly and indirectly held investees in providing software consulting services, selling and marketing computer-based business solutions and hardware products from a wide range of domestic and international manufacturers, as well as developing proprietary software solutions. It delivers solutions in Israel and in numerous countries to customers with complex IT services needs. It designs and implements IT solutions and software systems that improve the productivity of customers' existing IT assets, enable them to effectively manage their operations and reduce their business risks in the face of changing business environments.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.